Coherus BioSciences (CHRS) Expected to Announce Earnings on Monday

Coherus BioSciences (NASDAQ:CHRS) is projected to release its earnings data before the market opens on Monday, March 10th. Analysts expect Coherus BioSciences to post earnings of ($0.10) per share and revenue of $43.88 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Coherus BioSciences Price Performance

Shares of CHRS stock opened at $1.05 on Wednesday. The business’s 50 day simple moving average is $1.29 and its 200 day simple moving average is $1.19. Coherus BioSciences has a one year low of $0.66 and a one year high of $2.64. The stock has a market capitalization of $121.68 million, a PE ratio of -13.13 and a beta of 0.81.

Wall Street Analyst Weigh In

Several brokerages recently commented on CHRS. Robert W. Baird upped their target price on Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Coherus BioSciences in a report on Thursday, January 23rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $5.38.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.